Status | Study |
Completed |
Study Name: The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Condition: Central Serous Chorioretinopathy Date: 2012-10-16 Interventions: Drug: Intravitreal Aflibercept Injection GROUP A - Afliber |
Completed |
Study Name: Methotrexate for Central Serous Chorioretinopathy Treatment Trial Condition: Central Serous Chorioretinopathy Date: 2012-07-02 Interventions: Drug: Methotrexate 7.5 mg per |
Recruiting |
Study Name: The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Condition: Central Serous Chorioretinopathy Date: 2012-06-26 Interventions: Procedure: Photodynamic therapy Photodynamic therapy is performed using verteporfin. Full dose of vertep |
Completed |
Study Name: Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC) Condition: Central Serous Chorioretinopathy Date: 2012-04-08 Interventions: Procedure: PDT 30% or 50% verteporfin dose PDT was given to patients with CSC |
Completed |
Study Name: Central Serous Chorioretinopathy: Etiology, Course and Prognosis Condition: Central Serous Chorioretinopathy Date: 2011-06-20 |
Completed |
Study Name: Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy Condition: Central Serous Chorioretinopathy Date: 2011-03-29 Interventions: Procedure: Subthreshold diode micropulse laser |
Completed |
Study Name: Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Condition: Chronic Central Serous Chorioretinopathy Date: 2011-03-25 Interventions: Drug: Verteporfin a 6mg/m2 inf |
Completed |
Study Name: Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Condition: Central Serous Chorioretinopathy Date: 2009-11-19 Interventions: Drug: Verteporfin PDT, half-dose |
Completed |
Study Name: High-dose Antioxidants for Central Serous Chorioretinopathy Condition: Central Serous Chorioretinopathy Date: 2009-08-20 Interventions: Drug: antioxidants tablets vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc |
Completed |
Study Name: The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy Condition: Central Serous Chorioretinopathy Date: 2009-03-18 Interventions: Procedure: intravitreal injection with anterior paracentesis 0.1cc Aqueous humor samples were taken each |